The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma—A Feasibility Study
Abstract
The idiotype (Id) determinant on the multiple myeloma (MM) protein can be regarded as a tumor-specific marker. Immunotherapy directed at the MM Id may stem the progression of this disease. We report here on the first 12 MM patients treated at our institution with high-dose therapy and peripheral blood stem cell transplantation (PBSCT) followed by Id immunizations. MM patients received PBSCT to eradicate the majority of the disease. PBSCT produced a complete response in 2 patients, a partial response in 9 patients and stable disease in 1 patient. Three to 7 months after high-dose therapy, patients received a series of monthly immunizations that consisted of two intravenous infusions of Id-pulsed autologous dendritic cells (DC) followed by five subcutaneous boosts of Id/keyhole limpet hemocyanin (KLH) administered with adjuvant. Between 1 and 11 × 106 DC were obtained by leukapheresis in all patients even after PBSCT. The administration of Id-pulsed DC and Id/KLH vaccines were well tolerated with patients experiencing only minor and transient side effects. Two of 12 patients developed an Id-specific, cellular proliferative immune response and one of three patients studied developed a transient but Id-specific cytotoxic T-cell (CTL) response. Eleven of the 12 patients generated strong KLH-specific cellular proliferative immune responses showing the patients’ immunocompetence at the time of vaccination. The two patients who developed a cellular Id-specific immune response remain in complete remission. Of the 12 treated patients, 9 are currently alive after autologous transplantation with a minimum follow-up of 16 months, 2 patients died because of recurrent MM and 1 patient succumbed to acute leukemia. These studies show that patients make strong anti-KLH responses despite recent high-dose therapy and that DC-based Id vaccination is feasible after PBSCT and can induce Id-specific T-cell responses. Further vaccine development is necessary to increase the proportion of patients that make Id-specific immune responses. The clinical benefits of Id vaccination in MM remain to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804
Self-citationDendritic Cells: Unique Leukocyte Populations Which Control the Primary Immune Response
Hart, D. N. J. (1997) · Blood · doi:10.1182/blood.v90.9.3245 · Cited by 1,483
Romani, N., Reider, D., Heuer, M., Ebner, S., Kämpgen, E., Eibl, B., Niederwieser, D., & Schuler, G. (1996) · Journal of Immunological Methods · doi:10.1016/0022-1759(96)00078-6 · Cited by 1,091
Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.
Zhou, L. J., & Tedder, T. F. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2588 · Cited by 1,067
Kwak, L. W., Campbell, M. J., Czerwinski, D. K., Hart, S., Miller, R. A., & Levy, R. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210223271705 · Cited by 533
Self-citationHsu, F. J., Caspar, C. B., Czerwinski, D., Kwak, L. W., Liles, T. M., Syrengelas, A., Taidi-Laskowski, B., & Levy, R. (1997) · Blood · doi:10.1182/blood.v89.9.3129 · Cited by 452
Self-citationTricot, G. J. K., Jagannath, S., Vesole, D. H., Nelson, J., Tindle, S., Miller, L., Cheson, B. D., Crowley, J. J., & Barlogie, B. (1995) · Blood · doi:10.1182/blood.v85.2.588.588 · Cited by 452
Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation
Guillaume, T., Rubinstein, D. B., & Symann, M. (1998) · Blood · doi:10.1182/blood.v92.5.1471 · Cited by 323
Myeloma Proteins as Tumor-Specific Transplantation Antigens
Lynch, R. G., Graff, R. J., Sirisinha, S., Simms, E. S., & Eisen, H. N. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.6.1540 · Cited by 315
Allison, A. C., & Byars, N. E. (1986) · Journal of Immunological Methods · doi:10.1016/0022-1759(86)90402-3 · Cited by 315
Generation of Mature Dendritic Cells from Human Blood
Schuler, G., & Romani, N. (1997) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4757-9966-8_2 · Cited by 309
Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
Flamand, V., Sornasse, T., Thielemans, K., Demanet, C., Bakkus, M., Bazin, H., Tielemans, F., Leo, O., Urbain, J., & Moser, M. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240317 · Cited by 291
Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor
Kwak, L. W., Duffey, P. L., Reynolds, C. W., Longo, D. L., Taub, D. D., Bensinger, W. I., & Bryant, E. M. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90757-2 · Cited by 256
DNA immunization induces protective immunity against B–cell lymphoma
Syrengelas, A. D., Chen, T. T., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0996-1038 · Cited by 236
Self-citationÖsterborg, A., Yi, Q., Henriksson, L., Fagerberg, J., Bergenbrant, S., Jeddi-Tehrani, M., Rudén, U., Lefvert, A.-K., Holm, G., & Mellstedt, H. (1998) · Blood · doi:10.1182/blood.v91.7.2459 · Cited by 189
Campbell, M. J., Zelenetz, A. D., Levy, S., & Levy, R. (1992) · Molecular Immunology · doi:10.1016/0161-5890(92)90100-c · Cited by 180
Self-citationBogen, B. (1996) · European Journal of Immunology · doi:10.1002/eji.1830261119 · Cited by 161
Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors.
Lauritzsen, G. F., Weiss, S., Dembić, Z., & Bogen, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5700 · Cited by 139
Generation of antigen-specific CD8+ CTLs from naive precursors.
Mehta-Damani, A., Markowicz, S., & Engleman, E. G. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.3.996 · Cited by 137
Self-citationWen, Y. J., Ling, M., Bailey-Wood, R., et al. (1998) · PubMed · Cited by 130
Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma
Hsu, F. J., & Levy, R. (1995) · Blood · doi:10.1182/blood.v86.8.3072.3072 · Cited by 124
Self-citationCoon, J., & Hunter, R. L. (1973) · The Journal of Immunology · doi:10.4049/jimmunol.110.1.183 · Cited by 99
Naive CD4+ T cells confer idiotype‐specific tumor resistance in the absence of antibodies
Bogen, B., Munthe, L. A., Sollien, A., Hofgaard, P. O., Omholt, H., Dagnaes, F., Dembić, Z., & Lauritzsen, G. F. (1995) · European Journal of Immunology · doi:10.1002/eji.1830251114 · Cited by 81
Caspar, C. B., Levy, S., & Levy, R. (1997) · Blood · doi:10.1182/blood.v90.9.3699 · Cited by 56
Self-citationTarte, K., Lu, Z., Fiol, G., Legouffe, É., Rossi, J., & Klein, B. (1997) · Blood · doi:10.1182/blood.v90.9.3482 · Cited by 38
Takamizawa, M., Fagnoni, F. F., Mehta-Damani, A., Rivas, A., & Engleman, E. G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117654 · Cited by 36
Self-citation
Cited by
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Antigen Presentation and T Cell Stimulation by Dendritic Cells
Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C., & Amigorena, S. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064828 · Cited by 1,926
Dendritic Cells in Cancer Immunotherapy
Fong, L., & Engleman, E. G. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.245 · Cited by 680
Self-citationDendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
Ratta, M., Fagnoni, F., Curti, A., Vescovini, R., Sansoni, P., Oliviero, B., Fogli, M., Ferri, E., Della Cuna, G. R., Tura, S., et al. (2002) · Blood · doi:10.1182/blood.v100.1.230 · Cited by 442
Keyhole limpet hemocyanin (KLH): a biomedical review
Harris, J. R., & Markl∗, J. (1999) · Micron · doi:10.1016/s0968-4328(99)00036-0 · Cited by 373
Metadata
- Authors
- Reichardt, V. L., Okada, C. Y., Liso, A., Benike, C. J., Stockerl-Goldstein, K. E., Engleman, E. G., Blume, K. G., & Levy, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1999-04-01
- Volume
- 93
- Issue
- 7
- Pages
- 2411-2419
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W83009012
- Cited by
- 394
- References
- 31
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.